• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Oxford Biomedica Appoints Leone Patterson as Non-Executive Director

    4/26/23 7:00:00 AM ET
    $NKTX
    $TNYA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NKTX alert in real time by email

    Oxford Biomedica Appoints Leone Patterson as Non-Executive Director

    Oxford, UK – 26th April 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led viral vector CDMO, today announces the appointment of Ms Leone Patterson as an Independent Non-Executive Director. Ms Patterson shall join the Board on 1st May 2023.

    Ms Patterson has more than 20 years of public company biotech experience including in the cell and gene therapy industry and has managed significant growth within international commercial companies working across areas including strategy, finance, operations and governance.

    She is currently the Chief Financial and Business Officer at Tenaya Therapeutics (NASDAQ:TNYA), a clinical-stage company with a mission to discover, develop, and deliver potentially curative therapies, including gene therapy, for heart disease. Ms Patterson also serves on the Board of Directors for Nkarta (NASDAQ:NKTX), a clinical-stage cell therapy company. Previously, Ms Patterson held leadership roles, including Chief Executive Officer and Chief Financial Officer, at Adverum Biotechnologies, a gene therapy company focused on rare and ocular diseases. She has also held the role of Chief Financial Officer at public companies, including diagnostics firm Diadexus and speciality pharmaceuticals provider Transcept Pharmaceuticals and, earlier in her career, worked within Novartis, Chiron and KPMG. She holds a B.S. in business administration and accounting from Chapman University, an executive M.B.A. from St. Mary's College, and is a Certified Public Accountant (inactive).

    Dr. Roch Doliveux, Chair of Oxford Biomedica, said: "The appointment of Leone comes at an important juncture for Oxford Biomedica, as we advance our global leadership in viral vector development and supply, providing innovative solutions to our international biopharma customers. Leone's deep understanding of corporate finance, her experience of the US public markets and M&A, in addition to her extensive experience in the cell and gene therapy industry will be invaluable in supporting our international strategy and further strengthening our market position."

    Ms Leone Patterson said: "I am honoured to be joining the Board of Oxford Biomedica, a global innovation-led CDMO dedicated to enabling the development of life-saving cell and gene therapies. I look forward to working with the Board and contributing my expertise to help advance the Company's strategy."

    Diadexus voluntarily filed for Chapter 7 bankruptcy in June 2016 while Ms. Patterson was its Chief Financial Officer. Save as disclosed, there are no other disclosures required to be made in accordance with LR 9.6.13R.

    -Ends-

    Enquiries:        

    Oxford Biomedica plc:

    Taylor Boyd, VP, Head of IR – T: +1 (984) 268 8488/ E: [email protected]

    Sophia Bolhassan, VP, Corporate Affairs and IR – T: +44 (0) 7394 562 425 / E: [email protected]

    Consilium Strategic Communications:

    T: +44 (0)20 3709 5700 / E: [email protected]

    Mary-Jane Elliott / Matthew Neal / Davide Salvi

    About Oxford Biomedica

    Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

    One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

    Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and a US-based subsidiary, Oxford Biomedica Solutions, based near Boston, MA, US. Learn more at www.oxb.com, www.oxbsolutions.com, and follow us on LinkedIn, Twitter and YouTube.



    Primary Logo

    Get the next $NKTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NKTX
    $TNYA

    CompanyDatePrice TargetRatingAnalyst
    Nkarta Inc.
    $NKTX
    10/9/2024$14.00Buy
    Rodman & Renshaw
    Nkarta Inc.
    $NKTX
    8/14/2024$16.00Outperform → Strong Buy
    Raymond James
    Tenaya Therapeutics Inc.
    $TNYA
    6/10/2024Outperform
    William Blair
    Nkarta Inc.
    $NKTX
    3/22/2024$13.00 → $16.00Strong Buy → Outperform
    Raymond James
    Tenaya Therapeutics Inc.
    $TNYA
    11/30/2023$7.00Outperform
    Leerink Partners
    Nkarta Inc.
    $NKTX
    12/22/2022Outperform → Perform
    Oppenheimer
    Nkarta Inc.
    $NKTX
    10/10/2022$25.00Buy
    Canaccord Genuity
    Nkarta Inc.
    $NKTX
    7/28/2022$26.00Buy
    Needham
    More analyst ratings

    $NKTX
    $TNYA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Finance Higa Tomohiro sold $1,336 worth of shares (2,482 units at $0.54), decreasing direct ownership by 2% to 99,690 units (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      3/10/25 9:44:50 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer Tingley Whittemore sold $3,983 worth of shares (7,398 units at $0.54), decreasing direct ownership by 4% to 174,793 units (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      3/10/25 9:43:12 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Ali Faraz sold $5,245 worth of shares (9,741 units at $0.54), decreasing direct ownership by 3% to 320,514 units (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      3/10/25 9:42:17 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NKTX
    $TNYA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      Interim Data from Low Dose Cohort in MyPEAKTM-1 Clinical Trial of TN-201 Showed Encouraging Safety Profile, Transduction and Expression, Plus Improvements in Hypertrophy and NYHA Classification RIDGE Natural History and Seroprevalence Study Highlights Significant Disease Burden and Unmet Need Among Adults with PKP2-associated ARVC Data Readouts for TN-201 and TN-401 Clinical Programs On Track for the Second Half of 2025 Cash Runway Extended into Second Half of 2026 SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies tha

      5/7/25 4:05:00 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

      RIDGE is Largest Natural History Study Conducted with More Than 175 Participants Enrolled to Date with Arrhythmogenic Right Ventricular Cardiomyopathy Due to Mutations in the PKP2 Gene Patients Experience High Burden of Arrhythmias and Severe Disease Progression Despite Standard-of-Care Treatments Large Majority of PKP2-associated ARVC Patients Appear Eligible for TN-401 Gene Therapy Based on Low Rates of Preexisting Immunity to AAV9 Antibodies SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of hea

      4/24/25 2:07:47 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Nkarta to Participate in an April Investor Conference

      SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: 24th Annual Needham Virtual Healthcare ConferenceApril 8, 202511:00 a.m. ET – fireside chat   A simultaneous webcast of the event will be available on the Investors section of Nkarta's website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmu

      4/1/25 8:01:00 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NKTX
    $TNYA
    SEC Filings

    See more
    • SEC Form 10-Q filed by Tenaya Therapeutics Inc.

      10-Q - Tenaya Therapeutics, Inc. (0001858848) (Filer)

      5/7/25 4:27:33 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tenaya Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)

      5/7/25 4:18:33 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Tenaya Therapeutics Inc.

      SCHEDULE 13G - Tenaya Therapeutics, Inc. (0001858848) (Subject)

      5/7/25 9:31:20 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NKTX
    $TNYA
    Financials

    Live finance-specific insights

    See more

    $NKTX
    $TNYA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $NKTX
    $TNYA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $NKTX
    $TNYA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

      TN-201 Well Tolerated at 3E13 vg/kg Dose AAV9 Capsid Demonstrated Robust Delivery of TN-201 Transgene to Heart Muscle Cells Resulting in Increasing RNA Expression and an Increase in Protein Levels Observed at One Year Circulating Biomarkers and Other Clinical Measures Mostly Remained Stable or Improved from Baseline Tenaya Management to Host a Webcast Conference Call Today at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported encouraging

      12/17/24 7:00:00 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

      SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, will announce initial Cohort 1 data from the MyPEAK-1 Phase 1b/2 clinical trial of TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) on Tuesday, December 17. Conference Call and Webcast Tenaya management will host a live webcast and conference call to review the initial data from MyPEAK-1 on Tuesday, December 17th, 2024 at 8:00 a.m. ET. To access the live webcast, participants may register her

      12/16/24 4:30:00 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

      New pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapy NKX019, an allogeneic CAR NK cell therapy targeting CD19+ B cells, could modify refractory autoimmune disease while maintaining NK-driven safety profile Off-the-shelf accessibility and proprietary engineering could eliminate burdens of autologous products and may enable differentiating conditioning regimen Resource prioritization and cost reductions expected to extend cash runway by one year into 2026 to support important clinical data readouts in 2024 Estimated cash and cash equivalents of $278.4 mil

      10/17/23 7:01:00 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Nkarta Inc.

      SC 13G - Nkarta, Inc. (0001787400) (Subject)

      12/13/24 5:02:47 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tenaya Therapeutics Inc.

      SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

      11/14/24 5:46:12 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Nkarta Inc.

      SC 13G/A - Nkarta, Inc. (0001787400) (Subject)

      11/14/24 4:05:12 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rodman & Renshaw initiated coverage on Nkarta with a new price target

      Rodman & Renshaw initiated coverage of Nkarta with a rating of Buy and set a new price target of $14.00

      10/9/24 7:55:21 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nkarta upgraded by Raymond James with a new price target

      Raymond James upgraded Nkarta from Outperform to Strong Buy and set a new price target of $16.00

      8/14/24 7:45:34 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • William Blair initiated coverage on Tenaya Therapeutics

      William Blair initiated coverage of Tenaya Therapeutics with a rating of Outperform

      6/10/24 7:25:34 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Column Group Iii Gp, Lp bought $24,999,999 worth of shares (35,714,284 units at $0.70) (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      3/7/25 7:14:40 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Goeddel David V bought $24,999,999 worth of shares (35,714,284 units at $0.70) (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      3/7/25 7:14:15 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ra Capital Management, L.P. bought $30,000,000 worth of shares (3,000,000 units at $10.00) (SEC Form 4)

      4 - Nkarta, Inc. (0001787400) (Issuer)

      3/29/24 5:38:04 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NKTX
    $TNYA
    Leadership Updates

    Live Leadership Updates

    See more
    • Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

      SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing executive leadership responsibilities with Paul J. Hastings, who continues in his role as Chief Executive Officer. Additionally, Nkarta has broadened the role of David R. Shook, M.D., to Chief Medical Officer, Head of Research & Development. Drs. Mahmood and Shook will both report to Mr. Hastings. "This new leadership structure enables Nkarta to meet this transformative moment for cell therapy as

      7/16/24 6:01:00 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of

      5/15/24 4:05:00 PM ET
      $ENGN
      $NAMS
      $NKTX
      $PCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

      NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine (Flu/Ara-C) lymphodepletion regimenNKX019 clinical data presented at EHA 2023 and ICML 2023 meetingsClinical updates planned for NKX019 in the second half of 2023 and NKX101 in the first half of 2024Cash and cash equivalents of $302.2 million on June 30, 2023; cash runway anticipated to fund operations into 2025 SOUTH SAN FRANCISCO, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter ended June 30, 2

      8/10/23 7:01:00 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care